FDA looks to pull approval for Oncopeptides' troubled multiple myeloma drug Pepaxto

The odd saga of Oncopeptides' multiple myeloma drug—thriving in Europe while sidelined in the U.S.—continued Wednesday with the FDA requesting a withdrawal of the U.S. marketing authorization for Pepaxto.